Back to top
more

Travere Therapeutics (TVTX)

(Delayed Data from NSDQ)

$16.41 USD

16.41
4,328,178

-0.70 (-4.09%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $16.40 -0.01 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ligand (LGND) Up 3% on Raised '23 View, Beats on Q1 Earnings

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) announces better-than-expected results in first-quarter 2023. Management raises 2023 financial outlook.

Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Travere (TVTX) delivered earnings and revenue surprises of -7.63% and 11.90%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Meets Q3 Earnings Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of 0% and 0.74%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bristol Myers Squibb (BMY) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

Bristol Myers (BMY) delivered earnings and revenue surprises of 3.54% and 2.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Travere (TVTX) delivered earnings and revenue surprises of 0.96% and 1.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ligand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock Up

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) announces better-than-expected results in fourth-quarter 2022. Stock is up in the after-market hours in response to the news. Management raises 2023 financial outlook.

Earnings Preview: Denali Therapeutics Inc. (DNLI) Q4 Earnings Expected to Decline

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Travere Therapeutics (TVTX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Travere (TVTX) delivered earnings and revenue surprises of -12.37% and 4.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why Travere (TVTX) is Poised for a Turnaround After Losing 22.2% in 4 Weeks

by Zacks Equity Research

Travere (TVTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Travere (TVTX) delivered earnings and revenue surprises of -11.70% and 9.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Travere (TVTX) delivered earnings and revenue surprises of -41.18% and 8.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 12.82% and 85.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Travere (TVTX) delivered earnings and revenue surprises of -16.67% and 1.72%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Repligen (RGEN) delivered earnings and revenue surprises of 24.62% and 3.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Travere (TVTX) delivered earnings and revenue surprises of 18.06% and 32.98%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Travere Therapeutics (TVTX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere (TVTX) Announces Data on Rare Kidney Disease Drug

by Zacks Equity Research

Travere (TVTX) announces positive interim data from the ongoing study of its investigational candidate, sparsentan, for the treatment of IgAN, a rare kidney disorder. Resultantly, the stock rises

Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Travere (TVTX) delivered earnings and revenue surprises of 12.33% and 8.80%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?